Patents-Review.com
🔗 Permalink
Assignee profile:

SynDevRx, Inc.

City:

Cambridge, Massachusetts

Country:

United States

Published Applications:

20

Last publication date:

2023-07-20

Patent Grants:

19

Last grant date:

2025-09-23

Top Inventors for applications by SynDevRx, Inc.

These are the the leading inventors for applications assigned to SynDevRx, Inc.:

Recent patent applications by SynDevRx, Inc.

SynDevRx, Inc. based in Cambridge, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2023-07-20 ✅ Patent 12,419,846 granted on 2025-09-23
US20230225996A1
Human necessities

BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF

 #2 | 2023-06-01
US20230165892A1
Human necessities

POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF

 #3 | 2021-03-18 ✅ Patent 11,273,142 granted on 2022-03-15
US20210077452A1
Human necessities

Treatment for tumors driven by metabolic dysfunction

 #4 | 2020-05-21 ✅ Patent 11,304,944 granted on 2022-04-19
US20200155545A1
Human necessities

MetAP2 inhibitors and methods of treating obesity

 #5 | 2020-04-30 ✅ Patent 11,612,577 granted on 2023-03-28
US20200129457A1
Human necessities

Biomarkers of METAP2 inhibitors and applications thereof

 #6 | 2019-05-23 ✅ Patent 10,722,532 granted on 2020-07-28
US20190151353A1
Human necessities

Polymer-conjugated METAP2 inhibitors, and therapeutic methods of use thereof

 #7 | 2018-10-11 ✅ Patent 10,287,277 granted on 2019-05-14
US20180291010A1
Chemistry; metallurgy

Fumagillol derivatives and polymorphs thereof

 #8 | 2018-09-27 ✅ Patent 10,588,904 granted on 2020-03-17
US20180271856A1
Human necessities

METAP2 inhibitors and methods of treating obesity

 #9 | 2018-01-11 ✅ Patent 10,159,692 granted on 2018-12-25
US20180008630A1
Human necessities

Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof

 #10 | 2017-11-16 ✅ Patent 10,010,544 granted on 2018-07-03
US20170326135A1
Human necessities

METAP2 inhibitors and methods of treating obesity

 #11 | 2017-09-14 ✅ Patent 9,895,449 granted on 2018-02-20
US20170258925A1
Human necessities

Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof

 #12 | 2017-07-13 ✅ Patent 10,646,463 granted on 2020-05-12
US20170196830A1
Human necessities

Treatment for tumors driven by metabolic dysfunction

 #13 | 2017-06-15 ✅ Patent 9,969,722 granted on 2018-05-15
US20170166556A1
Chemistry; metallurgy

Fumagillol derivatives and polymorphs thereof

 #14 | 2017-02-02 ✅ Patent 9,757,373 granted on 2017-09-12
US20170028014A1
Human necessities

MetAP2 inhibitors and methods of treating obesity

 #15 | 2016-12-01 ✅ Patent 9,750,737 granted on 2017-09-05
US20160346244A1
Human necessities

METAP2 inhibitors and methods of treating obesity

 #16 | 2016-09-08 ✅ Patent 9,730,955 granted on 2017-08-15
US20160256483A1
Human necessities

Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof

 #17 | 2016-06-30 ✅ Patent 9,585,909 granted on 2017-03-07
US20160184345A1
Human necessities

Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof

 #18 | 2015-12-31 ✅ Patent 9,433,600 granted on 2016-09-06
US20150374657A1
Human necessities

METAP2 inhibitors and methods of treating obesity

 #19 | 2014-10-16 ✅ Patent 9,173,956 granted on 2015-11-03
US20140308235A1
Human necessities

METAP2 inhibitors and methods of treating obesity

 #20 | 2013-08-22 ✅ Patent 9,320,805 granted on 2016-04-26
US20130216494A1
Human necessities

Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof

Also check out SynDevRx, Inc.'s (Cambridge, United States) applicant profile with 18 patent applications submitted.

AssigneeID:

337630 ⎘